343 related articles for article (PubMed ID: 29391755)
1. circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling.
Guo XY; Sun F; Chen JN; Wang YQ; Pan Q; Fan JG
World J Gastroenterol; 2018 Jan; 24(3):323-337. PubMed ID: 29391755
[TBL] [Abstract][Full Text] [Related]
2. circRNA_0046367 Prevents Hepatoxicity of Lipid Peroxidation: An Inhibitory Role against Hepatic Steatosis.
Guo XY; Chen JN; Sun F; Wang YQ; Pan Q; Fan JG
Oxid Med Cell Longev; 2017; 2017():3960197. PubMed ID: 29018509
[TBL] [Abstract][Full Text] [Related]
3. Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells.
Zeng L; Tang W; Yin J; Feng L; Li Y; Yao X; Zhou B
Cell Physiol Biochem; 2016; 40(3-4):453-464. PubMed ID: 27889747
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic role of Artemether in the prevention of hepatic steatosis through miR-34a-5p/PPARα pathway.
Chen L; Yu S; Hong S; Lin X; Zhu X; Cao X; Li Y; Xiao H
Drug Dev Res; 2023 Apr; 84(2):156-171. PubMed ID: 36541217
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
[TBL] [Abstract][Full Text] [Related]
6. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease.
Ding J; Li M; Wan X; Jin X; Chen S; Yu C; Li Y
Sci Rep; 2015 Sep; 5():13729. PubMed ID: 26330104
[TBL] [Abstract][Full Text] [Related]
7. Suppression of miR-30a-3p Attenuates Hepatic Steatosis in Non-alcoholic Fatty Liver Disease.
Wang DR; Wang B; Yang M; Liu ZL; Sun J; Wang Y; Sun H; Xie LJ
Biochem Genet; 2020 Oct; 58(5):691-704. PubMed ID: 32419060
[TBL] [Abstract][Full Text] [Related]
8. MiR-34a regulates mitochondrial content and fat ectopic deposition induced by resistin through the AMPK/PPARα pathway in HepG2 cells.
Wen F; An C; Wu X; Yang Y; Xu J; Liu Y; Wang C; Nie L; Fang H; Yang Z
Int J Biochem Cell Biol; 2018 Jan; 94():133-145. PubMed ID: 29197627
[TBL] [Abstract][Full Text] [Related]
9. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
Liu J; Tang T; Wang GD; Liu B
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
[No Abstract] [Full Text] [Related]
10. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD.
Zheng L; Lv GC; Sheng J; Yang YD
J Gastroenterol Hepatol; 2010 Jan; 25(1):156-63. PubMed ID: 19780876
[TBL] [Abstract][Full Text] [Related]
11. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
[TBL] [Abstract][Full Text] [Related]
12. Sodium butyrate alleviates free fatty acid-induced steatosis in primary chicken hepatocytes via the AMPK/PPARα pathway.
Ding J; Liu J; Chen J; Cheng X; Cao H; Guo X; Hu G; Zhuang Y
Poult Sci; 2024 Apr; 103(4):103482. PubMed ID: 38387286
[TBL] [Abstract][Full Text] [Related]
13. Gan-Jiang-Ling-Zhu decoction alleviates hepatic steatosis in rats by the miR-138-5p/CPT1B axis.
Dang Y; Xu J; Zhu M; Zhou W; Zhang L; Ji G
Biomed Pharmacother; 2020 Jul; 127():110127. PubMed ID: 32325349
[TBL] [Abstract][Full Text] [Related]
14. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload.
Wang L; Sun M; Cao Y; Ma L; Shen Y; Velikanova AA; Li X; Sun C; Zhao Y
Arch Biochem Biophys; 2020 Nov; 695():108642. PubMed ID: 33098868
[TBL] [Abstract][Full Text] [Related]
15. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
[TBL] [Abstract][Full Text] [Related]
16. Isosilybin regulates lipogenesis and fatty acid oxidation via the AMPK/SREBP-1c/PPARα pathway.
Liu X; Hu M; Ye C; Liao L; Ding C; Sun L; Liang J; Chen Y
Chem Biol Interact; 2022 Dec; 368():110250. PubMed ID: 36347319
[TBL] [Abstract][Full Text] [Related]
17. Perfluoroalkyl acids-induced liver steatosis: Effects on genes controlling lipid homeostasis.
Das KP; Wood CR; Lin MT; Starkov AA; Lau C; Wallace KB; Corton JC; Abbott BD
Toxicology; 2017 Mar; 378():37-52. PubMed ID: 28049043
[TBL] [Abstract][Full Text] [Related]
18. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
[TBL] [Abstract][Full Text] [Related]
19. miR-26a Potentially Contributes to the Regulation of Fatty Acid and Sterol Metabolism In Vitro Human HepG2 Cell Model of Nonalcoholic Fatty Liver Disease.
Ali O; Darwish HA; Eldeib KM; Abdel Azim SA
Oxid Med Cell Longev; 2018; 2018():8515343. PubMed ID: 30402207
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1.
Wu GY; Rui C; Chen JQ; Sho E; Zhan SS; Yuan XW; Ding YT
Cell Physiol Biochem; 2017; 44(4):1651-1664. PubMed ID: 29216638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
